Tagged Articles

Invokana and Invokamet 43 articles

Europe requires lower limb amputation risk be added to Invokana safety label

European drug regulators have determined that new warnings regarding lower limb amputations should be added to the safety labels of type 2 diabetes drugs known as SGLT2 inhibitors. The warning is based on a European Medicine Agency (EMA) review of data from two ongoing clinical trials on SGLT2 inhibitors containing the active ingredient canagliflozin, which includes the brand name drugs Invokana and Invokamet (which sells under the name Vokanamet in Europe). One of the clinical trials is to determine canagliflozin’s impact on patients at high risk for cardiovascular events and the other is to assess affects on the kidneys. In ... Read More

Janssen study investigates effects of diabetes drug Invokana on kidneys

Just months after the Food and Drug Administration (FDA) strengthened kidney injury warnings for the type 2 diabetes drugs Invokana and Invokamet, the makers of the drug launched a study to investigate whether the treatment could protect patients against kidney impairment. The phase 3, randomized, double-blind, CREDENCE study conducted by Johnson & Johnson’s unit Janssen Pharmaceuticals is designed to study the effects of canagliflozin (the active ingredient in Invokana and Invokamet) on renal and cardiovascular outcomes in patients with type 2 diabetes and diabetic neuropathy. “The goal of this study is to assess whether canagliflozin has a renal and vascular ... Read More

NSAIDs, contrast dyes increase risk of kidney injury in diabetics taking Invokana

People taking Invokana or similar type 2 diabetes treatments are at increased risk of hypoxic kidney injury if they are dehydrated and/or during use of non-steroidal anti-inflammatory drugs (NSAIDs) or radiocontrast agents, according to a new study published in the journal Diabetes Care. The findings fall in step with recent Food and Drug Administration (FDA) warnings regarding an increased risk of acute kidney injury (AKI) with Invokana and Invokamet, which contain the active ingredient canagliflozin, and Farxiga and Xigudo XR, which contain the active ingredient dapagliflozin. Given that diabetes patients are at higher risk of kidney disease, researchers said that ... Read More

Invokana may be to blame for recurrent bladder infections resistant to treatment

To Your Health columnist Dr. Keith Roach agreed with a reader who pointed out that type 2 diabetics who suffer from recurrent bladder infections that are resistant to treatment may want to talk with their doctors about whether their diabetes medication may be exacerbating their condition. “It is known that UTIs (urinary tract infections) can be a side effect of certain medications that work through the bladder to flush excess glucose from the system (Invokana being one example of such a medication),” the reader wrote.” “You are right that SGLT2 inhibitors, such as canagliflozin (Invokana) and dapagliflozin (Farxiga), work by ... Read More

Safety label updates made to diabetes medication Gylxambi

New warnings have been added to the safety labels of the type 2 diabetes drug Gylxambi, the Food and Drug Administration (FDA) announced. Gylxambi is a combination of the diabetes drugs empagliflozin and linagliptin. Emphagliflozin is the active ingredient in the diabetes treatment Jardiance, which is in a class called SGLT2 inhibitors. Other drugs in this class include Invokana and Invokamet. Last year, the FDA required all SGLT2 inhibitors to include new warnings for serious urinary tract infections in patients taking the drugs, as well as an increased risk of ketoacidosis, a condition in which too much acid builds up ... Read More

Label of diabetes drug Synjardy updated to include new kidney risks

The Food and Drug Administration (FDA) approved updated information on the safety labels for the type 2 diabetes drug Synjardy to include an increased risk of acute kidney injury (AKI) and impairment of renal function. Synjardy was approved by the FDA in August 2015. It contains the active ingredients metformin and empagliflozin, the drug in the diabetes treatment Jardiance. Jardiance is in a class known as SGLT2 inhibitors, which also includes the brand names Invokana, Invokamet, Farxiga and Xigduo. The updated warning states, “Empagliflozin causes intravascular volume contraction and can cause renal impairment. There have been postmarketing reports of acute ... Read More

Diabetes drug effective in patients with high-carb diets, but low-carb diets pose DKA risk

Japanese drug maker Taisho Pharmaceuticals’ type 2 diabetes drug luseogliflozin, which is sold under the brand name Lusefi in Japan, is proving to be an effective treatment for diabetic patients who consume a diet that is made up of 40 to 55 percent carbohydrates, according to a study published recently in the journal Diabetes, Obesity and Metabolism. Luseogliflozin was approved by Japanese drug regulators in 2014 but is currently not sold in the United States. It is in a newer class of type 2 diabetes drugs known as SGLT2 inhibitors, which includes the brand name drugs Invokana and Invokamet. The latest ... Read More

Rob Kardashian hospitalized after ‘diabetes scare’

Television personality Rob Kardashian was released from the hospital after a “diabetes scare” sent him to the hospital. Best known for his role on Keeping Up with the Kardashians and its spinoffs, as well as a turn on Dancing with the Stars, Rob was diagnosed nearly a year ago with type 2 diabetes after developing diabetic ketoacidosis (DKA) a serious condition in which too much acid builds up in the blood. If left untreated, DKA can lead to diabetic coma and death. Following his diagnosis, Rob vowed to lose weight and adopt a healthier lifestyle to help combat the chronic ... Read More

FDA monitoring severe dehydration risk with diabetes drug Farxiga

The Food and Drug Administration (FDA) is monitoring reports of severe dehydration in patients taking the type 2 diabetes drug Farxiga and has updated the “Warnings and Precautions” section on the safety label about the risk of acute kidney injury (AKI), according to the FDA’s April 1, 2016 to June 30, 2016, review of postmarket drug safety evaluations. The agency’s website provides summary information about ongoing and completed postmarket safety evaluations of adverse experience reports made to the FDA to determine if there are any new serious adverse events not previously identified during product development, known side effects reported in ... Read More

Invokana timeline reveals growing list of warnings

In March 2013, the Food and Drug Administration (FDA) approved a novel new type 2 diabetes treatment called Invokana. The drug, manufactured by Johnson & Johnson’s Janssen Pharmaceuticals, was the first in a class of diabetes drugs known as SGLT2 inhibitors. Unlike other diabetes medications that work through the pancreas or liver, Invokana lowers blood sugar by pushing excess sugar through the kidneys where it is excreted through the urine. The drug was almost an immediate hit, offering the benefit of weight loss to a population of patients often plagued by obesity. Other drugs, such as the Invokana and insulin ... Read More